Warfarin pharmacogenetics

Trends in Cardiovascular Medicine

Volumn 25, Issue 1, 2015, Pages 33-41

  Johnson, Julie A ^a   Cavallari, Larisa H ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; CYTOCHROME P450 2C9; VKORC1 PROTEIN, HUMAN;

AFRICAN AMERICAN; ALGORITHM; ALLELE; CAUCASIAN; DISEASE MARKER; ETHNICITY; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; META ANALYSIS (TOPIC); MINORITY GROUP; PATIENT CARE; PHARMACOGENETICS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; GENETICS;

ANTICOAGULANTS; CYTOCHROME P-450 CYP2C9; GENOTYPE; HUMANS; PHARMACOGENETICS; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84919665546     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2014.09.001     Document Type: Review

References (43)

1. Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013, 369:799-808.
2. Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
3. Investigators E., Bauersachs R., Berkowitz S.D., Brenner B., Buller H.R., Decousus H., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
4. Kirley K., Qato D.M., Kornfield R., Stafford R.S., Alexander G.C. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012, 5:615-621.
5. Budnitz D.S., Lovegrove M.C., Shehab N., Richards C.L. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011, 365:2002-2012.
6. Limdi N.A., McGwin G., Goldstein J.A., Beasley T.M., Arnett D.K., Adler B.K., et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2008, 83:312-321.
7. Limdi N.A., Wadelius M., Cavallari L., Eriksson N., Crawford D.C., Lee M.T., et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010, 115:3827-3834.
8. Rieder M.J., Reiner A.P., Gage B.F., Nickerson D.A., Eby C.S., McLeod H.L., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005, 352:2285-2293.
9. Niinuma Y., Saito T., Takahashi M., Tsukada C., Ito M., Hirasawa N., et al. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J 2014, 14:107-114.
10. Perera M.A., Gamazon E., Cavallari L.H., Patel S.R., Poindexter S., Kittles R.A., et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 2011, 89:408-415.
11. Caldwell M.D., Awad T., Johnson J.A., Gage B.F., Falkowski M., Gardina P., et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008, 111:4106-4112.
12. Cha P.C., Mushiroda T., Takahashi A., Kubo M., Minami S., Kamatani N., et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 2010, 19:4735-4744.
13. Bress A., Patel S.R., Perera M.A., Campbell R.T., Kittles R.A., Cavallari L.H. Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics 2012, 13:1925-1935.
14. McDonald M.G., Rieder M.J., Nakano M., Hsia C.K., Rettie A.E. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 2009, 75:1337-1346.
15. Perera M.A., Cavallari L.H., Limdi N.A., Gamazon E.R., Konkashbaev A., Daneshjou R., et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 2013, 382:790-796.
16. Jorgensen A.L., FitzGerald R.J., Oyee J., Pirmohamed M., Williamson P.R. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One 2012, 7:e44064.
17. Wadelius M., Chen L.Y., Lindh J.D., Eriksson N., Ghori M.J., Bumpstead S., et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009, 113:784-792.
18. Limdi N.A., Arnett D.K., Goldstein J.A., Beasley T.M., McGwin G., Adler B.K., et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 2008, 9:511-526.
19. Cooper G.M., Johnson J.A., Langaee T.Y., Feng H., Stanaway I.B., Schwarz U.I., et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008, 112:1022-1027.
20. Takeuchi F., McGinnis R., Bourgeois S., Barnes C., Eriksson N., Soranzo N., et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009, 5:e1000433.
21. Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh S.L., Farin F.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J Am Med Assoc 2002, 287:1690-1698.
22. Yang J., Chen Y., Li X., Wei X., Chen X., Zhang L., et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. Int J Cardiol 2013, 168:4234-4243.
23. Finkelman B.S., Gage B.F., Johnson J.A., Brensinger C.M., Kimmel S.E. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol 2011, 57:612-618.
24. Gage B.F., Eby C., Johnson J.A., Deych E., Rieder M.J., Ridker P.M., et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008, 84:326-331.
25. International Warfarin Pharmacogenetics Consortium, Klein T.E., Altman R.B., Eriksson N., Gage B.F., Kimmel S.E., et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 360:753-764.
26. Schelleman H., Chen J., Chen Z., Christie J., Newcomb C.W., Brensinger C.M., et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther 2008, 84:332-339.
27. Lenzini P., Wadelius M., Kimmel S., Anderson J.L., Jorgensen A.L., Pirmohamed M., et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 2010, 87:572-578.
28. Anderson J.L., Horne B.D., Stevens S.M., Woller S.C., Samuelson K.M., Mansfield J.W., et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 2012, 125:1997-2005.
29. Kimmel S.E., French B., Kasner S.E., Johnson J.A., Anderson J.L., Gage B.F., et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013, 369:2283-2293.
30. Pirmohamed M., Burnside G., Eriksson N., Jorgensen A.L., Toh C.H., Nicholson T., et al. Arandomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013, 369:2294-2303.
31. Avery P.J., Jorgensen A., Hamberg A.K., Wadelius M., Pirmohamed M., Kamali F., et al. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther 2011, 90:701-706.
32. Verhoef T.I., Redekop W.K., Daly A.K., van Schie R.M., de Boer A., Maitland-van der Zee A.H. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br J Clin Pharmacol 2014, 77:626-641.
33. Cavallari L.H., Langaee T.Y., Momary K.M., Shapiro N.L., Nutescu E.A., Coty W.A., et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010, 87:459-464.
34. Holbrook A., Schulman S., Witt D.M., Vandvik P.O., Fish J., Kovacs M.J., et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e152S-e1584.
35. Johnson J.A., Gong L., Whirl-Carrillo M., Gage B.F., Scott S.A., Stein C.M., et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011, 90:625-629.
36. Stergiopoulos K., Brown D.L. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. J Am Med Assoc Intern Med 2014, 174:1330-1338.
37. Liao Z., Feng S., Ling P., Zhang G. Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing. J Thromb Thrombolysis 2014.
38. Hernandez W., Gamazon E.R., Aquino-Michaels K., Patel S., O'Brien T.J., Harralson A.F., et al. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. Pharmacogenomics J 2014, 14:223-228.
39. Gonzalez Burchard E., Borrell L.N., Choudhry S., Naqvi M., Tsai H.J., Rodriguez-Santana J.R., et al. Latino populations: a unique opportunity for the study of race, genetics, and social environment in epidemiological research. Am J Public Health 2005, 95:2161-2168.
40. Shahin M.H., Khalifa S.I., Gong Y., Hammad L.N., Sallam M.T., El Shafey M., et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics 2011, 21:130-135.
41. Lee S.C., Ng S.S., Oldenburg J., Chong P.Y., Rost S., Guo J.Y., et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 2006, 79:197-205.
42. Do E.J., Lenzini P., Eby C.S., Bass A.R., McMillin G.A., Stevens S.M., et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J 2012, 12:417-424.
43. Nutescu E.A., Drozda K., Bress A.P., Galanter W.L., Stevenson J., Stamos T.D., et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy 2013, 33:1156-1164.